Table 3.
Immune responses in breast cancer patients
| Patient no. |
CD4 assay1 |
ELISPOT2 CEA |
MUC-1 | IL-83 | IL-63 | TNF-α3 |
|---|---|---|---|---|---|---|
| 1 | + >4X | − | − | ↓ | ↓ | ↓ |
| 8 | + >2.3X | NA | NA | ↑ | ↑ | ↑ |
| 12 | − | + >7.7X | + >9.1X | NC | NC | NC |
| 13 | − 4 | − | − | ↑ | NC | ↑ |
| 23 | − | NA | NA | ↓ | NC | NC |
| 24 | +5>8X | NA6 | NA6 | ↓ | ↓ | ↓ |
| 25 | NA | NA | NA | ↓ | NC | ↑ |
1
> 3-fold increase in stimulation index was considered positive.
2
ELISPOT was performed with in vitro stimulation with HLA-A2 restricted CEA and MUC-1 peptides along with HIV peptide controls (which were all negative).
3
> 2-fold increase or decrease in cytokine assays was considered positive or negative, respectively.
4
Patient had high CD4 function pre-vaccination.
5
Test turned positive on day 154.
6
Patient had inadequate pre-vaccine sample available for testing; however, had a positive ELISPOT response to CEA on day 71 following vaccine.
NA = not applicable; NC = no change.